Serratia Bacteremia in a Large University Hospital: Trends in Antibiotic Resistance During 10 Years and Implications for Antibiotic Use

Objective: To identify antibiotic resistance trends and risk factors for resistance of Serratia species to third-generation cephalosporins. Design: Retrospective survey of medical records. Setting: A 2,200-bed, tertiary-care hospital. Patients: One hundred twenty-two patients with Serratia bacteremia between January 1991 and June 2001. Methods: Infectious disease physicians collected data from medical records regarding patient demographics, underlying disease or condition, portal of entry, microorganism, antibiogram, complications, antibiotics received, and outcome. Results: Among 122 Serratia isolates, 117 (95.9%) were Serratia marcescens and 110 (90.2%) were of nosocomial origin. During the study period, the 122 isolates showed a high rate of resistance to third-generation cephalosporins (45.9%) and extended-spectrum penicillins (56.6%). The resistance rate to ciprofloxacin was 32.0%. The resistance rate to third-generation cephalosporins increased from 31.7% for 1991 to 1995 to 54.9% for 1996 to 1998 and 50.0% for 1999 to 2001. In the multivariate analysis, prior use of a second-generation cephalosporin (adjusted odds ratio [OR], 5.90; 95% confidence interval [CI95], 1.41 to 24.6; P = .015) or a third-generation cephalosporin (OR, 3.26; CI95, 1.20 to 8.87; P = .020) was a strong independent risk factor for resistance to third-generation cephalosporins. The overall case-fatality rate was 25.4% (Serratia bacteremia-related case-fatality rate, 13.1%). Conclusion: Prior use of a second- or third-generation cephalosporin was the most important risk factor for bacteremia with Serratia resistant to third-generation cephalosporins, suggesting the need for antibiotic control. The potential role of patient-to-patient spread could not be fully evaluated in this retrospective study.

[1]  K. Kaye,et al.  Pathogens resistant to antimicrobial agents. Epidemiology, molecular mechanisms, and clinical management. , 2004, Infectious disease clinics of North America.

[2]  S. Cosgrove,et al.  Risk Factors for Emergence of Resistance to Broad-Spectrum Cephalosporins among Enterobacterspp , 2001, Antimicrobial Agents and Chemotherapy.

[3]  L. Grohskopf,et al.  Serratia liquefaciens bloodstream infections from contamination of epoetin alfa at a hemodialysis center. , 2001, The New England journal of medicine.

[4]  K. D. Allen,et al.  Critical care unit outbreak of Serratia liquefaciens from contaminated pressure monitoring equipment. , 2001, The Journal of hospital infection.

[5]  K. Kaye,et al.  PATHOGENS RESISTANT TO ANTIMICROBIAL AGENTS , 2000 .

[6]  D. McClish,et al.  Nosocomial bloodstream infections in United States hospitals: a three-year analysis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  J. Bosso,et al.  Impact of use of multiple antimicrobials on changes in susceptibility of gram-negative aerobes. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  R A Weinstein,et al.  Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. , 1999, JAMA.

[9]  W. L. Yu,et al.  Serratia marcescens bacteremia: clinical features and antimicrobial susceptibilities of the isolates. , 1998, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[10]  Ronald N. Jones,et al.  Important and emerging beta-lactamase-mediated resistances in hospital-based pathogens: the Amp C enzymes. , 1998, Diagnostic microbiology and infectious disease.

[11]  D. F. Sahm,et al.  AmpC beta-lactamases. , 1998 .

[12]  M. Samore,et al.  The molecular and clinical epidemiology of enterobacteriaceae-producing extended-spectrum β-lactamase in a tertiary care hospital* , 1998 .

[13]  J. Ariza,et al.  Epidemiology and Successful Control of a Large Outbreak Due to Klebsiella pneumoniae Producing ExtendedSpectrum β-Lactamases , 1998, Antimicrobial Agents and Chemotherapy.

[14]  G. Jacoby.  EXTENDED-SPECTRUM β-LACTAMASES AND OTHER ENZYMES PROVIDING RESISTANCE TO OXYIMINO-β-LACTAMS , 1997 .

[15]  Ronald N. Jones,et al.  Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). , 1997, Diagnostic microbiology and infectious disease.

[16]  J. Pitout,et al.  Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli. , 1997, The American journal of medicine.

[17]  C. V. van Boven,et al.  Serratia marcescens infections in neonatal departments: description of an outbreak and review of the literature. , 1997, The Journal of hospital infection.

[18]  R A Weinstein,et al.  Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. , 1996, The Journal of infectious diseases.

[19]  A. M. Oberheu,et al.  Nosocomial infection in the community hospital: severe infection due to Serratia species. , 1996, The Journal of family practice.

[20]  S. Cohen,et al.  The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I beta-lactamase-producing organisms. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  D. Livermore.  beta-Lactamases in laboratory and clinical resistance , 1995, Clinical microbiology reviews.

[22]  D. Livermore,et al.  Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A beta-lactamase, Sme-1, from Serratia marcescens S6 , 1994, Antimicrobial Agents and Chemotherapy.

[23]  K S Meyer,et al.  Nosocomial Outbreak of Klebsiella Infection Resistant to Late-Generation Cephalosporins , 1993, Annals of Internal Medicine.

[24]  P M Bennett,et al.  Molecular basis of beta-lactamase induction in bacteria , 1993, Antimicrobial Agents and Chemotherapy.

[25]  Christine C. Sanders,et al.  β-Lactam Resistance in Gram-Negative Bacteria: Global Trends and Clinical Impact , 1992 .

[26]  S. Sokalski,et al.  An outbreak of Serratia marcescens in 14 adult cardiac surgical patients associated with 12-lead electrocardiogram bulbs. , 1992, Archives of internal medicine.

[27]  V L Yu,et al.  Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. , 1991, Annals of internal medicine.

[28]  J. Gourgand,et al.  A case-control study of an outbreak of infections caused by Klebsiella pneumoniae strains producing CTX-1 (TEM-3) beta-lactamase. , 1991, The Journal of hospital infection.

[29]  N. Clark,et al.  Epidemic of Serratia marcescens bacteremia in a cardiac intensive care unit , 1989, Journal of clinical microbiology.

[30]  L. Elting,et al.  Serratia bacteremia: review of 118 cases. , 1989, Reviews of infectious diseases.

[31]  C. Sanders,et al.  Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins. , 1988, Reviews of infectious diseases.

[32]  F. AlonsoNavas,et al.  [Serratia marcescens bacteremia: a study of 83 cases]. , 1988 .

[33]  Fry De,et al.  Serratial bacteremia in the surgical patient. , 1987 .

[34]  B. Andersen,et al.  Nosocomial outbreak of nitrate-negative Serratia marcescens infections , 1982, Journal of clinical microbiology.

[35]  V L Yu,et al.  Serratia marcescens: historical perspective and clinical review. , 1979 .

[36]  S. Levitsky,et al.  Outbreak of Serratia marcescens Infections in a Cardiothoracic Surgical Intensive Care Unit , 1975 .

[37]  J. G. Crowder,et al.  Serratia marcescens Bacteremia: Clinical Observations and Studies of Precipitin Reactions , 1971 .

[38]  F. Barrett,et al.  Bacteremia due to serratia marcescens. , 1968, The New England journal of medicine.

[39]  C. Morel,et al.  ["Serratia marcescens" septicemia]. , 1965, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris.

[40]  G. Jackson,et al.  Gram-Negative Bacteremia. II. Clinical, Laboratory, and Therapeutic Observations. , 1962 .

[41]  M. Samore,et al.  The molecular and clinical epidemiology of enterobacteriaceae-producing extended-spectrum beta-lactamase in a tertiary care hospital. , 1998, The Journal of infection.

[42]  G. Jacoby.  Extended-spectrum beta-lactamases and other enzymes providing resistance to oxyimino-beta-lactams. , 1997, Infectious disease clinics of North America.

[43]  M. Viñas,et al.  Lipopolysaccharide recovery restores susceptibility levels towards beta-lactams in Serratia marcescens. , 1995, Microbios.

[44]  W. W. Wong,et al.  Serratia marcescens bacteremia. , 1991, Journal of the Formosan Medical Association = Taiwan yi zhi.

[45]  C. Watanakunakorn.  Serratia bacteremia: a review of 44 episodes. , 1989, Scandinavian journal of infectious diseases.

[46]  J. Miro,et al.  Nosocomial bacteremia in a large Spanish teaching hospital: analysis of factors influencing prognosis. , 1988, Reviews of infectious diseases.

[47]  E. Bouza.  Serratia bacteremia. , 1988, Diagnostic microbiology and infectious disease.

[48]  D. Fry,et al.  Serratial bacteremia in the surgical patient. , 1987, The American surgeon.

[49]  R. Leng,et al.  SERRATIA MARCESCENS IN A NEWBORN UNIT‐MICROBIOLOGICAL FEATURES , 1984, Pathology.

[50]  John E. Bennett,et al.  Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .

[51]  S. Levitsky,et al.  Outbreaks of Serratia marcescens infections in a cardiothoracic surgical intensive care unit. , 1975, The Annals of thoracic surgery.